BR0315328A - Método de administração de bisfosfonatos - Google Patents

Método de administração de bisfosfonatos

Info

Publication number
BR0315328A
BR0315328A BR0315328-2A BR0315328A BR0315328A BR 0315328 A BR0315328 A BR 0315328A BR 0315328 A BR0315328 A BR 0315328A BR 0315328 A BR0315328 A BR 0315328A
Authority
BR
Brazil
Prior art keywords
bisphosphonates
months
administration method
bisphosphonate administration
bisphosphonate
Prior art date
Application number
BR0315328-2A
Other languages
English (en)
Inventor
Victor Sloan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR0315328A publication Critical patent/BR0315328A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"MéTODO DE ADMINISTRAçãO DE BISFOSFONATOS". A presente invenção refere-se a bisfosfonatos, em particular a N-bisfosfonatos mais potentes tais como ácido zoledrónico e derivados, que podem ser usados com resultados satisfatórios para tratamento de artrite reumatóide através de administração intermitente, onde os períodos entre administrações de bisfosfonato são de cerca de dois meses a cerca de quatro meses, por exemplo uma vez a cada três meses.
BR0315328-2A 2002-10-15 2003-10-14 Método de administração de bisfosfonatos BR0315328A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41855502P 2002-10-15 2002-10-15
PCT/EP2003/011380 WO2004035061A1 (en) 2002-10-15 2003-10-14 Method of administering bisphosphonates

Publications (1)

Publication Number Publication Date
BR0315328A true BR0315328A (pt) 2005-08-16

Family

ID=32107944

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0315328-2A BR0315328A (pt) 2002-10-15 2003-10-14 Método de administração de bisfosfonatos

Country Status (9)

Country Link
US (3) US20050272705A1 (pt)
EP (1) EP1553958A1 (pt)
JP (1) JP2006506365A (pt)
CN (1) CN1705485A (pt)
AU (1) AU2003280373A1 (pt)
BR (1) BR0315328A (pt)
CA (1) CA2501381A1 (pt)
TW (1) TW200410701A (pt)
WO (1) WO2004035061A1 (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101597262A (zh) 2002-03-05 2009-12-09 特兰斯泰克制药公司 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物
BRPI0707516A2 (pt) * 2006-02-06 2011-05-10 Cypress Bioscience Inc composiÇÕes que compreendem um bisfosfonato e um antifolato
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CN102573809B (zh) 2009-07-31 2017-07-21 格兰泰股份有限公司 结晶方法和生物利用度
TWI517850B (zh) 2009-09-30 2016-01-21 Ｖｔｖ治療有限責任公司 經取代之咪唑衍生物及其使用方法
CN102190684A (zh) * 2010-03-15 2011-09-21 南通波锐生物医药有限公司 一种具有药物应用的含磷化合物及其制备和用途
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US8865757B1 (en) 2014-05-28 2014-10-21 Antecip Bioventures Ii Llp Therapeutic compositions comprising imidazole and imidazolium compounds
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9655908B2 (en) 2012-05-14 2017-05-23 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9675626B2 (en) 2012-05-14 2017-06-13 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9289441B2 (en) 2014-08-08 2016-03-22 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9662343B2 (en) 2012-05-14 2017-05-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9616078B2 (en) 2012-05-14 2017-04-11 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9669040B2 (en) 2012-05-14 2017-06-06 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
EP2849758B1 (en) * 2012-05-14 2018-04-04 Antecip Bioventures II LLC Compositions comprising zoledronic acid or related compounds for relieving inflammatory pain and related conditions
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US8802658B2 (en) 2012-05-14 2014-08-12 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9427403B2 (en) 2012-05-14 2016-08-30 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
PL2932852T3 (pl) 2012-05-24 2017-07-31 Dow Global Technologies Llc Kompozycja biobójcza
KR101739244B1 (ko) * 2013-10-25 2017-05-23 안테씨프 바이오벤쳐스 투 엘엘씨 질병의 치료를 위한, 졸레드론산 또는 관련 화합물의 경구 투여용 조성물
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US10195218B2 (en) 2016-05-31 2019-02-05 Grunenthal Gmbh Crystallization method and bioavailability
CN107365330B (zh) * 2017-07-10 2019-07-12 石家庄学院 二氢杨梅素双膦酸单钠盐衍生物及其制备方法和应用
CN112533612A (zh) * 2018-06-26 2021-03-19 弗兰克·哈洛克·埃比蒂诺 骨靶向抗微生物噁唑烷酮相关化合物、其制剂及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0650361T3 (da) * 1992-06-30 1999-06-23 Procter & Gamble Pharma Sammensætninger til behandling af arthritis, hvilke sammensætninger indeholder phosphonater og NSAID'er
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
US8052987B2 (en) * 2000-06-20 2011-11-08 Novartis Pharmaceuticals Corporation Method of administering bisphosphonates

Also Published As

Publication number Publication date
US20080227755A1 (en) 2008-09-18
US20050272705A1 (en) 2005-12-08
WO2004035061A1 (en) 2004-04-29
US20070161603A1 (en) 2007-07-12
CN1705485A (zh) 2005-12-07
CA2501381A1 (en) 2004-04-29
EP1553958A1 (en) 2005-07-20
JP2006506365A (ja) 2006-02-23
AU2003280373A1 (en) 2004-05-04
TW200410701A (en) 2004-07-01

Similar Documents

Publication Publication Date Title
BR0315328A (pt) Método de administração de bisfosfonatos
BR0111806A (pt) Método de administração de bisfosfonatos
ATE493413T1 (de) Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
BRPI0415639A (pt) formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia
BR112018010024A8 (pt) compostos e composições úteis no tratamento de distúrbios relacionados a ntrk
ATE449183T1 (de) Verfahren zur herstellung von dipeptiden oder dipeptidderivaten.
BRPI0509172A (pt) pelo menos uma entidade quìmica, composição farmacêutica, métodos para tratar um paciente, para inibir pelo menos uma enzima que utiliza atp, e para tratar pelo menos uma doença, uso de pelo menos uma entidade quìmica, e, método para a fabricação de um medicamento
NO20081878L (no) Diacylindazolderivater som lipase- og fosfolipaseinhibitorer
NO20052923L (no) Fusjonerte bicykliske nitrogeninneholdende heteroringer
BRPI0507830A (pt) derivados azabicìclicos, o respectivo processo de preparo e as composições farmacêuticas que os contêm
MY140514A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MXPA05007792A (es) Prodrogas de propofol derivadas de aminoacido, composiciones y usos de las mismas.
HRP20041013B1 (hr) Formulacija visoke doze ibandronata
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
MX2022003969A (es) Composiciones degustables que incluyen fenilbutirato de sodio y usos de las mismas.
BR9909234A (pt) Método para fornecimento de glutamina
CY1109496T1 (el) Τρυγικο και φωσφορικο αλας της 3,4-διαμινοπυριδινης, φαρμακευτικες συνθεσεις και χρησεις αυτων
DK2046813T3 (da) Proteinbindende methotrexat-derivater og lægemiddel indeholdende disse
NO20073549L (no) Fremgangsmate for fremstilling av organiske forbindelser
MY140530A (en) Antineoplasic compounds and pharmaceuticals compositions thereof
ATE409186T1 (de) Derivate von 4,7-dioxobenzothiazol-2- carbonsäureamiden, verfahren zu deren herstellung und deren therapeutische anwendungen
HUP0300219A2 (hu) L-nukleozidokat, L-nukleotidokat és analógjaikat tartalmazó készítmények és alkalmazásuk
DE602006010111D1 (de) Pharmazeutische formulierung zur behandlung von osteoarthritis mit clodronsäure und hyaluronsäure
DE602004017214D1 (de) Antibakterielle und/oder gegen protozoen wirksame nitroimidazolderivatverbindungen mit ureasehemmender wirkung, verfahren zur herstellung dieser verbindungen und deren verwendung in pharmazeutischen zusammensetzungen und medikamenten

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2160 DE 29/05/2012.